Literature DB >> 33092694

Molecular and epidemiological surveillance of polymyxin-resistant Klebsiella pneumoniae strains isolated from Brazil with multiple mgrB gene mutations.

Kesia Esther da Silva1, To Nguyen Thi Nguyen2, Christine J Boinett3, Stephen Baker4, Simone Simionatto5.   

Abstract

The prevalence of polymyxin-resistant Enterobacteriaceae is increasing worldwide. Their emergence is worrisome and limits therapeutic options for severely ill patients. We aimed to investigate the molecular and epidemiological characteristics of polymyxin-resistant Klebsiella pneumoniae circulating in Brazilian hospitals. Polymyxin-resistant K. pneumoniae isolates from two Brazilian healthcare facilities were characterized phenotypically and subjected to whole genome sequencing (WGS). Using the WGS data we determined their sequence type, resistance gene content (resistome), their composition of virulence genes and plasmids. ST11 was the most common (80 %) sequence type among the isolates followed by ST345, ST15 and ST258. A resistome analysis revealed the common presence of blaKPC-2 and less frequently blaSHV-11, blaTEM-1, blaCTX-M-15, and blaOXA-9. Genes conferring resistance to aminoglycosides, fluoroquinolones, phenicols, sulphonamides, tetracyclines, trimethoprim and macrolide-lincosamide-streptogramin were also detected. We observed a clonal spread of polymyxin-resistant K. pneumoniae isolates, with polymyxin-resistance associated with various alterations in the mgrB gene including inactivation by an insertion sequence and nonsense point mutations. We additionally identified a novel 78-bp repeat sequence, encoding a MgrB protein with 26 amino acids duplicated in six isolates. This is the first observation of this type of alteration being associated with polymyxin resistance. Our findings demonstrate that mgrB alterations were the most common source of polymyxin-resistance in Brazilian clinical settings. Interestingly, distinct genetic events were identified among clonally related isolates, including a new amino acid alteration. The clinical implications and investigation of the resistance mechanisms is of great importance to patient safety and control of these infections, particularly in long-term care facilities.
Copyright © 2020 The Authors. Published by Elsevier GmbH.. All rights reserved.

Entities:  

Keywords:  Intensive Care Unit (ICU); Klebsiella pneumoniae; Nucleotide sequencing; Polymyxin-resistance; mgrB

Mesh:

Substances:

Year:  2020        PMID: 33092694     DOI: 10.1016/j.ijmm.2020.151448

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  4 in total

Review 1.  Overview of polymyxin resistance in Enterobacteriaceae.

Authors:  Kesia Esther da Silva; Luana Rossato; Andressa Ferraz Leite; Simone Simionatto
Journal:  Rev Soc Bras Med Trop       Date:  2022-02-25       Impact factor: 1.581

2.  Polymyxin Resistance in Clinical Isolates of K. pneumoniae in Brazil: Update on Molecular Mechanisms, Clonal Dissemination and Relationship With KPC-Producing Strains.

Authors:  Orlando C Conceição-Neto; Bianca Santos da Costa; Leilane da Silva Pontes; Melise Chaves Silveira; Lívia Helena Justo-da-Silva; Ivson Cassiano de Oliveira Santos; Camila Bastos Tavares Teixeira; Thamirys Rachel Tavares E Oliveira; Fernanda Stephens Hermes; Teca Calcagno Galvão; L Caetano M Antunes; Cláudio Marcos Rocha-de-Souza; Ana P D Carvalho-Assef
Journal:  Front Cell Infect Microbiol       Date:  2022-07-15       Impact factor: 6.073

3.  Genetic Diversity of Virulent Polymyxin-Resistant Klebsiella aerogenes Isolated from Intensive Care Units.

Authors:  Kesia Esther da Silva; Gleyce Hellen de Almeida de Souza; Quézia Moura; Luana Rossato; Letícia Cristina Limiere; Nathalie Gaebler Vasconcelos; Simone Simionatto
Journal:  Antibiotics (Basel)       Date:  2022-08-19

Review 4.  MgrB Mutations and Altered Cell Permeability in Colistin Resistance in Klebsiella pneumoniae.

Authors:  Polly Soo-Xi Yap; Wan-Hee Cheng; Sook-Keng Chang; Swee-Hua Erin Lim; Kok-Song Lai
Journal:  Cells       Date:  2022-09-26       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.